Anika Therapeutics (ANIK) Other financing activities (2010 - 2025)

Anika Therapeutics (ANIK) has 16 years of Other financing activities data on file, last reported at -$261000.0 in Q4 2025.

• On a quarterly basis, Other financing activities changed N/A year-over-year to -$261000.0 in Q4 2025; TTM through Sep 2025 was $261000.0, a 69.08% decrease from a year earlier, with the FY2024 full-year figure at $76000.0, down 90.56% from the prior year.
• Other financing activities for Q4 2025 stood at -$261000.0, down from $261000.0 in the prior quarter.
• Over the last five years, Other financing activities for ANIK reached as high as $768000.0 in Q4 2023 and fell as low as -$1.0 million in Q4 2021.
• Historically, Other financing activities has averaged $64071.4 across 5 years, with a median of $19500.0 in 2022.
• On a YoY basis, Other financing activities climbed as much as 4700.0% in 2023 and fell as far as 2693.33% in 2023.
• Year by year, Other financing activities stood at -$1.0 million in 2021, then jumped by 101.58% to $16000.0 in 2022, then surged by 4700.0% to $768000.0 in 2023, then sank by 93.1% to $53000.0 in 2024, then sank by 592.45% to -$261000.0 in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were -$261000.0 in Q4 2025, $261000.0 in Q3 2025, and $53000.0 in Q2 2024.